纤溶酶联合阿托伐他汀治疗短暂性脑缺血发作的疗效观察

目的探讨注射用纤溶酶联合阿托伐他汀钙片治疗短暂性脑缺血发作的临床效果。方法选取2015年1月—2016年7月乐山市中医医院收治的短暂性脑缺血患者90例,按随机数字表法将患者分为对照组和治疗组,每组各45例。对照组静脉滴注注射用纤溶酶,首次剂量100 U加入到5%葡萄糖注射液250 mL,再次剂量加倍,输注时间60 min,1次/d。治疗组在对照组基础上睡前口服阿托伐他汀钙片,2片/次,1次/d。两组均连续治疗6个月。观察两组的临床疗效,比较两组的血液流变学指标和血脂水平。结果治疗后,对照组和治疗组的总有效率分别为75.6%、91.1%,两组比较差异有统计学意义(P0.05)。治疗后,两组纤维蛋白原(FIB)、全血低切黏度(LBV)、全血高切黏度(HBV)、血浆黏度(SV)和血小板聚集率(PAR)明显降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组三酰甘油(TG)、总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)水平显著降低,而高密度脂蛋白胆固醇(HDL-C)水平显著升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论注射用纤溶酶联合阿托伐他汀钙片治疗短暂性脑缺血发作具有较好的临床疗效,能改善血液流变学指标和血脂水平,安全性较好,具有一定的临床推广应用价值。

Clinical observation of fibrinogenase combined with atorvastatin in treatment of transient ischemic attack

Objective To investigate the effect of Fibrinogenase for injection combined with Atorvastatin Calcium Tablets in treatment of transient ischemic attack. Methods Patients (90 cases) with transient ischemic attack in Leshan Hospital of Traditional Chinese Medicine from January 2015 to July 2016 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were iv administered with Fibrinogenase for injection, first dose 100 U added into 5% glucose solution 250 mL, then double dose, infusion time for 60 min, once daily. Patients in the treatment group were po administered with Atorvastatin Calcium Tablets on the basis of the control group before going to bed, 2 tablets/time, once daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and blood rheology indexes and blood lipid levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 75.6% and 91.1%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of FIB, LBV, HBV, SV, and PAR in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of TG, TC, and LDL-C in two groups were significantly decreased, but the levels of HDL-C in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Fibrinogenase for injection combined with Atorvastatin Calcium Tablets has clinical curative effect in treatment of transient ischemic attack, can improve blood rheology indexes and blood lipid level, with good safety, which has a certain clinical application value.